ArticleMolecular medicine (Cambridge, Mass.)2015
Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients.
Article in Molecular medicine (Cambridge, Mass.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- PIWI family proteins as prognostic markers in cancer: a systematic review and meta-analysis.Cellular and molecular life sciences : CMLS · 2020Pooled it
- Expression of progranulin (GP88) protein appears as an independent prognostic factor for clinical progression in high-risk prostate cancer patients.Scientific reports · 2026Article
- Piwil-2 represents a poor prognosticator in Merkel cell carcinomas that regulates oncoproteins, cell cycle arrest and SOX-2 expression.Scientific reports · 2025Article
- The Role of PIWI-Interacting RNA in Urologic Carcinoma and Its Clinical Implications.Cancer reports (Hoboken, N.J.) · 2025Review
- Decreased Expression Levels Of PIWIL2, PIWIL3 and PIWIL4 Are Associated with Poor Prognosis and Worse Survival in Bladder Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Dexmedetomidine promotes colorectal cancer progression via Piwil2 signaling.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Prognostic and Predictive Potential of CCL5 Expression in Muscle-Invasive Bladder Cancer Patients.International journal of molecular sciences · 2024Article
- Elevated expression patterns of P-element Induced Wimpy Testis (PIWI) transcripts are potential candidate markers for Hepatocellular Carcinoma.Cancer biomarkers : section A of Disease markers · 2024Article
- PIWI-interacting RNA (piRNA): a narrative review of its biogenesis, function, and emerging role in lung cancer.Asian biomedicine : research, reviews and news · 2022Review
- piRNAs and PIWI Proteins as Diagnostic and Prognostic Markers of Genitourinary Cancers.Biomolecules · 2022Review
- Article
- PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer.Cancers · 2020Article
- Article
- Article
- Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients.Cancers · 2019Article
- [Predictive biomarkers in bladder cancer].Der Pathologe · 2019Review
- Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients.Scientific reports · 2019Article
- Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet.Frontiers in genetics · 2019Review
- Piwi-interacting RNAs (piRNAs) and cancer: Emerging biological concepts and potential clinical implications.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Piwi-like 2 (Piwil 2) belongs to the family of Argonaute genes/proteins. The expression of Piwil 2 is associated with stem cells. A role in tumorigenesis and/or tumor progression is proposed for different cancers but not yet for bladder cancer (BCa). We investigated the Piwil 2 expression by immunohistochemistry in a cohort of 202 BCa patients treated by cystectomy and adjuvant chemotherapy. The association between Piwil 2 expression and disease-specific (DSS) or progression-free survival (PFS) was calculated using Kaplan Meier analyses and univariate/multivariate Cox's regression hazard models.In a multivariate Cox's regression, Piwil 2 expression, either in the cytoplasm or the nucleus, was significantly associated with DSS and PFS. A weak cytoplasmic staining pattern was associated with poor DSS and tumor progression (RR=2.7; P=0.004 and RR=2.4; P=0.027). Likewise,, absent nuclear Piwil 2 immunoreactivity was associated with poor DSS and tumor progression (RR=2.3; P=0.023 and RR=2.2; P=0.022). BCa patients whose tumors exhibited a combination of weak cytoplasmic and absent nuclear immunoreactivity had a 6-fold increased risk of tumor-related death (P=0.005) compared to patients with strong expression. Considering only patients with high grade G3 tumors, a 7.8-fold risk of tumor-associated death and a 3.6-fold risk of tumor progression were detected independently of the histologic tumor subtype or the chemotherapy regimen. In summary, a combination of weak cytoplasmic and absent nuclear expression of Piwil 2 is significantly associated with an increased risk of DSS and tumor progression. This implicates that Piwil 2 could be a valuable prognostic marker for high-risk BCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.